PubMed · 14209040
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A S TILL, M D MIDDLETON. 1964. PERICYSTITIS PLASTICA.. https://doi.org/10.1111/j.1464-410x.1964.tb09528.x
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
PURPOSE OF REVIEW: In recent years nitric oxide (NO) has gained increasing recognition as an important neurotransmitter and cell signaling molecule with a broad range of functions in the lower urinary tract. This review discusses recently published data related to the physiologic and pathophysiologic roles of NO and nitric oxide synthase (NOS) in the female lower urinary tract. RECENT FINDINGS: Expression of three isoforms of NOS, namely endothelial NOS, neuronal NOS and inducible NOS, has been identified in various tissues of the lower urinary tract in animals and humans. In addition to its relaxation effects on bladder and urethra, NO also serves as a neurotransmitter in the lower urinary tract. The physiologic roles of NO in overactive bladder, bladder outlet obstruction, diabetic cystopathy, interstitial cystitis, and bladder inflammation have been demonstrated. SUMMARY: NO plays an important role in the micturition process and in disorders of the lower urinary tract. Improved understanding of the pathophysiologic role of NO/NOS system and of the L-arginine-NO-cGMP pathway may allow us to identify suitable therapeutic targets for lower urinary tract disorders. However, there is a need for further investigation to determine the precise function of NO in human lower urinary tract because most work thus far has been done in animal models.
Explore the source record for details and available documents.
PURPOSE: The aim of this study was to quantify ocular refractive changes after a standard hyperbaric oxygen (HBO) treatment protocol and to characterize the time period of recovery. PATIENTS AND METHODS: Hyperbaric oxygen therapy was given for 90 min daily at a pressure of 240 kPa for 21 days. Oxygen was administered to 20 patients using an oronasal mask and to 12 patients using a hood. Follow-up examinations were carried out 2-4 days after treatment, and thereafter regularly for up to 10 weeks in both groups. Refraction was assessed automatically and by the monocular subjective refraction method. A subgroup of nine of the 20 patients to whom oxygen was administered by an oronasal mask underwent a separate eye examination, which included crystalline lens opacity measurements and LOCS III gradings. RESULTS: In the patients given oxygen by mask, there was a significant myopic shift in the mean spherical equivalent, which was largest 2-4 days after treatment. The shift was - 0.55 +/- 0.40 D in the right eye and - 0.53 +/- 0.42 D in the left eye. In the patients given oxygen by hood, the largest shift was observed after 12-16 days, and was - 1.06 +/- 0.52 D in the right eye and - 1.10 +/- 0.57 D in the left eye. The refractive changes returned to baseline 6 weeks and 10 weeks after HBO treatment, respectively. No significant changes in crystalline lens transparency were revealed. CONCLUSIONS: The myopic shift after HBO therapy recovers within 10 weeks and may be more pronounced when patients are given oxygen using a hood compared with using an oronasal mask.